

28 August 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SAILIFE	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
--	--

Sub: Press Release regarding commencement of second phase of production block.

Ref: Intimation dated 20 June 2025.

Dear Sir/ Madam,

In continuation to our intimation dated 20 June 2025 regarding the commencement of second phase of the production block with ≈91 kL of capacity at its facility in Bidar, Karnataka, India (“Unit IV Bidar Facility”) on 19 June 2025, please find attached a copy of press release in this regard.

We request you to take note of the same.

Thank you.

For **Sai Life Sciences Limited**

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above.

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com



PRESS RELEASE

Sai Life Sciences completes Phase II of Production Block 11 at Bidar, India, expands capacity to 700 KL

August 28, 2025, Hyderabad: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused [Contract Research, Development, and Manufacturing Organization \(CRDMO\)](#), today announced the completion of Phase II of its new Production Block (PB-11) at the company's flagship API manufacturing facility in Bidar, India (Unit IV).

The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL, making it the single largest reactor volume block at the Bidar site. This expansion has taken the company's total installed reactor capacity at the Bidar facility to ~700 KL.

Making the announcement, **Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences**, said: *"Our clients are at the heart of everything we do. This expansion at Bidar is more than additional capacity – it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programs. By strengthening our large-scale API and intermediate manufacturing, we are enabling our clients to move faster, de-risk their supply chains, and bring new medicines to market with greater assurance."*

PB-11 is a multi-purpose production block designed to handle large-scale commercial products. Sai Life Sciences' Unit IV in Bidar is the company's flagship manufacturing site, specializing in the production of APIs and advanced intermediates for highly regulated markets such as the US, EU, and Japan. Key highlights include:

- 12 production blocks with a combined capacity of ~700 KL
- Dedicated facilities for high-potency APIs (HPAPIs)
- State-of-the-art QC laboratories ensuring compliance and product integrity
- Advanced capabilities such as lyophilization, cryogenic reactions, high-pressure reactions, and commercial-scale chromatography

The facility has been successfully inspected and approved by leading global regulatory agencies including the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, Sai Life Sciences' manufacturing units had undergone over 75 customer audits in the past three years, reflecting its uncompromising commitment to quality, safety, and compliance.

About Sai Life Sciences:

Sai Life Sciences is a leading integrated contract research, development, and manufacturing organisation (CRDMO). We work with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, we have served a diverse set of programmes, consistently delivering value based on our quality and responsiveness. We have over 3,400 employees across our facilities in India, UK and USA. <https://www.sailife.com/>

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communication
Sai Life Sciences Limited
Ph: +91 9121295355
sriram.g@sailife.com